444620-34-2 Usage
Uses
Used in Pharmaceutical Industry:
1-Boc-4-(1,2,3,4-tetrahydroisoquinolin-8-yl)piperazine is used as a potential therapeutic agent for the development of new drug candidates due to its unique chemical structure and potential biological activities. Its properties make it a promising candidate for further research and development in medicinal chemistry.
Used in Medicinal Chemistry Research:
1-Boc-4-(1,2,3,4-tetrahydroisoquinolin-8-yl)piperazine is used as a building block for the synthesis of new molecules with enhanced pharmacological properties. Its unique structure allows for the creation of novel compounds that may exhibit improved therapeutic effects and reduced side effects.
Used in Drug Discovery and Development:
1-Boc-4-(1,2,3,4-tetrahydroisoquinolin-8-yl)piperazine is used as a ligand in the design of new molecules for drug discovery and development. Its interaction with biological targets can provide insights into the development of more effective and targeted therapeutic agents in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 444620-34-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,4,6,2 and 0 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 444620-34:
(8*4)+(7*4)+(6*4)+(5*6)+(4*2)+(3*0)+(2*3)+(1*4)=132
132 % 10 = 2
So 444620-34-2 is a valid CAS Registry Number.
InChI:InChI=1/C18H27N3O2/c1-18(2,3)23-17(22)21-11-9-20(10-12-21)16-6-4-5-14-7-8-19-13-15(14)16/h4-6,19H,7-13H2,1-3H3
444620-34-2Relevant academic research and scientific papers
Privileged structure-based ligands for melanocortin receptors - Tetrahydroquinolines, indoles, and aminotetralines
Fisher, Matthew J.,Backer, Ryan T.,Husain, Saba,Hsiung, Hansen M.,Mullaney, Jeffrey T.,O'Brian, Thomas P.,Ornstein, Paul L.,Rothhaar, Roger R.,Zgombick, John M.,Briner, Karin
, p. 4459 - 4462 (2007/10/03)
Substitution of the aryl sulfonamide moiety contained in MC4 agonist 1 with bicyclic heterocycles and aminotetralines produced compounds with MC4 activity. The heterocycles represent alternative privileged structures to that contained in 1. Compounds in which the polar group of the privileged structure was displayed in an endocyclic fashion were not as active as the parent agonist 1, while those with an exocyclic polar group afforded activity competitive with 1.
